Neuphoria Therapeutics Inc. (NEUP)
NASDAQ: NEUP · Real-Time Price · USD
4.670
+0.180 (4.01%)
Jun 8, 2026, 4:00 PM EDT - Market closed
Neuphoria Therapeutics Revenue
Neuphoria Therapeutics had revenue of $-13.27K in the twelve months ending March 31, 2026. In the fiscal year ending June 30, 2025, Neuphoria Therapeutics had annual revenue of $15.65M.
Revenue (ttm)
$-13.27K
Revenue Growth
n/a
P/S Ratio
-1,902.41
Revenue / Employee
n/a
Employees
8
Market Cap
25.24M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 15.65M | - | - |
| Jun 30, 2024 | - | - | - |
| Jun 30, 2023 | - | - | - |
| Jun 30, 2022 | 4.17M | 3.48M | 499.60% |
| Jun 30, 2021 | 695.81K | -1.37M | -66.32% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Celularity | 26.55M |
| Barinthus Biotherapeutics | 14.97M |
| Palatin Technologies | 12.88M |
| Dyadic International | 3.81M |
| Marker Therapeutics | 3.55M |
| Pluri | 1.08M |
| Allarity Therapeutics | 345.00K |
NEUP News
- 24 days ago - Neuphoria Therapeutics downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 24 days ago - Neuphoria Therapeutics Quarterly report: Q3 2026 - Filings
- 3 months ago - Neuphoria Therapeutics Quarterly report: Q2 2026 - Filings
- 6 months ago - Neuphoria announces ISS recommends shareholders vote ‘FOR’ director nominees - TheFly
- 6 months ago - Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director Nominees - GlobeNewsWire
- 6 months ago - Neuphoria Therapeutics Proxy statement: Proxy filing - Filings
- 6 months ago - Neuphoria Therapeutics price target lowered to $7 from $21 at H.C. Wainwright - TheFly
- 6 months ago - Neuphoria Therapeutics responds to Lynx1’s revised indication of interest - TheFly